Lupin Partners with Valorum Biologics for US Launch of Cancer Biosimilar Armlupeg
Key Insights
Lupin Ltd (search) has signed an exclusive licensing agreement with US-based Valorum Biologics for the commercialization and distribution of its biosimilar Armlupeg (search) (pegfilgrastim-unne (search)) in the United States.
The biosimilar is indicated to reduce neutropenia (search) duration and febrile neutropenia (search) risk in chemotherapy patients, serving as a biosimilar to Neulasta.
Under the partnership, Lupin will manufacture and supply the drug from its FDA-inspected Pune facility while receiving upfront licensing fees and royalties on net sales.
Lupin Ltd (search) announced on December 4th that it has entered into an exclusive licensing agreement with US-based Valorum Biologics for its cancer (search) biosimilar Armlupeg (search) (pegfilgrastim-unne (search)), marking a strategic expansion into the American biosimilars market. Under the partnership terms, Valorum will handle commercialization and distribution activities in the US, while Lupin retains manufacturing and supply responsibilities.
The financial structure includes an upfront license fee for Lupin along with ongoing royalty payments based on net sales performance. This arrangement allows Lupin to leverage Valorum's US market expertise while maintaining control over production quality and supply chain management.
Recent FDA Approval Strengthens Market Position
The licensing agreement follows closely on the heels of significant regulatory progress. Earlier this week, the US Food and Drug Administration (search) approved Armlupeg (search) as a 6mg/0.6ml injection for subcutaneous use in a single-dose pre-filled syringe format. The product serves as a biosimilar to Neulasta (pegfilgrastim), a widely used supportive care medication in oncology.
Pegfilgrastim-unne (search) is indicated to reduce the duration of neutropenia (search) and the incidence of febrile neutropenia (search) in patients receiving chemotherapy. These conditions represent serious complications of cancer (search) treatment that can delay therapy and increase infection risk.
Manufacturing and Quality Assurance
Production of Armlupeg (search) will take place at Lupin's biotech facility in Pune, India. The FDA conducted a pre-approval inspection of this facility, demonstrating the company's commitment to meeting stringent US regulatory standards for biosimilar manufacturing.
"We look forward to strengthening our presence in the US biosimilars market and building on our momentum as a global leader in developing and commercialising important biosimilar medicines," stated Spiro Gavaris, president of US Generics at Lupin.
Market Response and Strategic Implications
Despite the positive business development, Lupin's shares showed minimal movement, ending 0.38% higher at Rs 2,088 on the NSE. The stock has declined 11.6% year-to-date, suggesting investors may be taking a cautious approach to the company's biosimilar initiatives.
The partnership represents Lupin's broader strategy to establish a stronger foothold in the competitive US biosimilars market, where the company aims to build on its global experience in developing and commercializing biosimilar medicines. The collaboration model allows for risk-sharing while potentially accelerating market entry through Valorum's established US distribution networks.